New study sheds light on language development in children with hearing loss

A University of Miami study offers new insights into language development in children with hearing loss, suggesting language learning strategies that may help children with cochlear implants-surgically implanted hearing devices-overcome initial language development delays.

The study, conducted by University of Miami College of Arts and Sciences researchers Lynn K. Perry and Daniel S. Messinger and University of Miami Leonard M. Miller School of Medicine researcher Ivette Cejas, sheds light on the relationship between early vocabulary knowledge and later language development in children with cochlear implants.

The researchers focused on the proportion of shape-based nouns in children’s initial vocabularies. Shape-based nouns are words like “chair” or “cup” that describe a category of objects based on their shape, rather than other characteristics such as color or material.

Their findings, published in Developmental Science, show that a higher proportion of shape-based nouns in a child’s vocabulary shortly after cochlear implantation was associated with better language development for the next three years.

The researchers also found that the association between the shape-based nouns and long-term language development was stronger in children who had received cochlear implants, compared to children with normal hearing. The results have implications for efforts to help children with hearing loss surmount initial language delays caused by a lack of auditory input and access to speech sounds before they receive cochlear implants.

“Learning more shape-based nouns seemed to affect both how many words they knew and also their grammar skills and other aspects of language,” said Perry, the first author on the paper and an associate professor in the Department of Psychology. “Especially for the children with cochlear implants, it was such a strong predictor that even three years later, we were able to account for some of the differences in their language skills.”

The data used in this study was collected as part of the Childhood Development after Cochlear Implantation Study, a national, multi-site longitudinal study. The researchers analyzed data on the language abilities of young children with cochlear implants prior to their implantation surgery and every six months after implantation. They also looked at data on children with normal hearing who were recruited from preschools.

The study, which was supported by the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health, found that the children with a larger proportion of shape-based nouns in their vocabularies shortly after implantation had larger vocabularies at a year, two years, and three years after implantation. They also scored higher on standardized tests of other language abilities, and they were more likely to have caught up with their peers with normal hearing.

Previous studies have indicated the importance of shape-based nouns in the language development of children with normal hearing, and that picking up on this pattern in early-learned English vocabulary can help children to acquire new words. But prior to this study, little was known about the role of shape-based nouns in the language development of children with cochlear implants.

“This is a real experiment in nature showing that the types of words a child knows shape their language development,” said Messinger, a professor in the Department of Psychology. “It’s remarkable that these effects were strongest for cochlear implant users, perhaps because shape-based nouns guided their word learning after implants gave them access to hearing.”

The findings suggest that knowing shape-based nouns facilitates children’s language development and may help to make up for initial language delays in children with cochlear implants.

“While cochlear implants have become the standard of care for children with bilateral severe to profound hearing loss, there continues to be significant variability in their spoken language development,” said Cejas, a professor and the director of family support services in the Department of Otolaryngology at the Miller School of Medicine. “Our work highlights a potential avenue for intervention that may aid in closing the vocabulary and language gap that exists for some of these children.”

Although the study found an association between the initial proportion of shape-based nouns in a child’s vocabulary and later language development, the researchers said further investigation is needed to establish a causal link.

They also noted that they don’t yet know why some children had a larger proportion of shape-based nouns in their vocabulary than others.

“Both within the group of children who have cochlear implants and children in general, we do see differences in terms of what words children learn first,” Perry said. “I think figuring out where those differences come from will be important to knowing how to best support all learners.”

Reference:

Lynn K. Perry, Daniel S. Messinger, Ivette Cejas, Vocabulary Composition Shapes Language Development in Children With Cochlear Implants, Developmental Science,  https://doi.org/10.1111/desc.13588

Powered by WPeMatico

First American Gastroenterological Association living guideline for moderate-to-severe ulcerative colitis

The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published today in Gastroenterology. This guideline groups the 12 currently available advanced treatments based on efficacy, to simplify the decision-making process for gastroenterologists and the approximately 1.25 million patients in the U.S. living with ulcerative colitis.

“Since the first biologic treatment for ulcerative colitis was introduced in 2005, 11 advanced therapies have become available in the U.S.,” said guideline author Ashwin N. Ananthakrishnan. “AGA’s updated guidelines integrate both tried-and-true treatments and the latest advancements, offering patients and providers the most current recommendations for managing moderate-to-severe ulcerative colitis.”

To streamline treatment selection, AGA categorized drugs with similar efficacy into “efficacy buckets” that allow clinicians to consider a range of effective treatments based on the likelihood of inducing remission, regardless of the drug’s mechanism. Comparative efficacy recommendations in the guideline are based on a systematic review and network meta-analysis (Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis – Gastroenterology) of published evidence. Using this rigorous process resulted in practical, trustworthy guidance to help patients and clinicians evaluate multiple factors to tailor care, rather than selecting a single “best” treatment.

Key factors influencing treatment decisions include a patient’s risk of disease complications, disease severity, and other considerations such as comorbidities, age, safety risks, and pregnancy status. Additionally, prior treatment history can impact the effectiveness of subsequent therapies, underscoring the importance of personalized treatment planning.

Treatment recommendations:

• AGA recommends patients with moderate-to-severe ulcerative colitis start with advanced therapies and/or immunomodulators over a step-up approach following 5-aminosalicylates (5-ASA) failure.

• For patients who have not previously received advanced therapies, the medications with the highest efficacy include infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab and guselkumab.

• Among patients with prior exposure to advanced therapies, particularly those who have experienced TNF antagonist failure, the medications with the highest efficacy are tofacitinib, upadacitinib, and ustekinumab.

As a living guideline, semiannual reviews of this body of evidence will be conducted by the authors, and recommendations will be updated when indicated.

Understanding ulcerative colitis

There are two main types of inflammatory bowel disease (IBD)-ulcerative colitis and Crohn’s disease. Ulcerative colitis causes inflammation (swelling) and sores (called ulcers) in the large intestine (colon and rectum) and may affect part or all of the large intestine. Ulcerative colitis can happen at any age, but it is more likely to develop in people between the ages of 15 and 40. While there is no cure for ulcerative colitis, there are many options to help treat it, and the medications described in this AGA guideline can lead to remission (periods of no symptoms). 

Reference:

Siddharth Singh, Edward V. Loftus, AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis, Gastroenterology, DOI:10.1053/j.gastro.2024.10.001.

Powered by WPeMatico

Pharmacists Must Now Mandatorily Verify Profiles with ABHA Number: PCI

New Delhi: In a move to integrate pharmacists into the Healthcare Professional Registry (HPR) under the Ayushman Bharat Digital Mission (ABDM), the Pharmacy Council of India has directed all registered pharmacists and pharmacy institutions to mandatorily verify their profiles with the Ayushman Bharat Health Account (ABHA) number on the DIGI-PHARMed portal.

Through its recent notification, PCI said that it is verifying the profiles of all registered pharmacists on the DIGI-PHARMed portal to facilitate seamless integration with the Healthcare Professional Registry (HPR).

“All registered Pharmacists are requested to verify their DIGI-PHARMed Profile with the ABIHA Number on immediate basis. The said verification must be completed within the timeline of 45 Days from the date of issuance of this circular.” the Council said.

“Failing to this, the pharmacist’s profile will be disabled for any further usage on the DIGI-PHARMed portal,” PCI added.

Also Read: Up to 3 Months Jail, Rs 2 Lakh Fine if Unregistered Persons Found Operating Pharmacy: Chhattisgarh Pharmacy Council

The Council further clarified that incase of new registration, pharmacists must validate their accounts with the ABHA number at the time of registration. Without this verification, the registration will be deemed incomplete.

Furthermore, pharmacists who do not yet have an ABHA number have been directed to create one using Aadhaar before initiating the registration process.

Additionally, pharmacy institutions are instructed to ensure that all faculty members have verified ABHA profiles. Starting from the 2025-26 academic session, PCI will only consider ABHA-verified profiles for Standard Inspection Format (SIF) applications and other academic references.

The council emphasized that all documents uploaded to the DIGI-PHARMed portal during registration must be authentic and validated. Any discrepancies in submitted documents will result in blacklisting the pharmacist’s profile.

“If the Council discovers at any stage that any documents submitted during the registration process are incorrect, the respective profile of those pharmacists will be blacklisted,” warned the Council.

Pharmacists or institutions encountering technical difficulties during this process can report issues via email at pcihelpinfo@gmail.com or contact PCI support at +91-7303110019.

HPR is a comprehensive repository of registered and verified different system of medicines (modern medicine, dentistry, Ayurveda, Unani, Siddha, Sowa-Rigpa, Homoeopathy) and nurses practitioners delivering healthcare services across India.

To initiate registration, click on the link: https:/rabha.abdm. eov. in iabha i vJ/res.ister/aadhaar

Also Read: Fake Pharmacy Certificates Scam: Nine Chemists, 2 Ex-Registrars, 1 superintendent of Punjab State Pharmacy Council arrested

Powered by WPeMatico

USFDA accepts for review application for GSK Blenrep combinations for multiple myeloma treatment

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep (belantamab mafodotin) in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for the treatment of patients with multiple myeloma who have received at least one prior line of therapy. The US FDA has assigned a Prescription Drug User Fee Act action date of 23 July 2025.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said, “Relapsed/refractory multiple myeloma treatment could be transformed by additional, efficacious treatment options with manageable side effects and community-based administration. The evidence from DREAMM-7 and DREAMM-8 supporting our Blenrep combinations submission has been further strengthened by the statistically significant overall survival results from the DREAMM-7 trial. We look forward to working with the FDA on this review.”

The US application is based on results from the DREAMM-7 and DREAMM-8 phase III trials, which both met their primary endpoints, showing statistically significant and clinically meaningful improvements in progression-free survival (PFS) for the belantamab mafodotin combinations compared to standard of care triplet combinations in relapsed or refractory multiple myeloma.

Results from both trials also showed clinically meaningful improvements across all other secondary efficacy endpoints, including deeper and more durable responses compared to the respective standard of care combinations. The safety and tolerability profiles of the belantamab mafodotin combinations in the DREAMM-7 and DREAMM-8 trials were broadly consistent with the known profiles of the individual agents.

In a subsequent planned interim analysis, the DREAMM-7 trial also met the key secondary endpoint of overall survival (OS), showing a statistically significant and clinically meaningful OS benefit favouring the belantamab mafodotin combination. Efficacy and safety data from this analysis will be presented at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition on 9 December 2024 at 11:15 a.m. PT. A positive trend in OS was observed in DREAMM-8 but was not statistically significant at the time of interim analysis, and follow-up for OS continues.

This is the sixth major regulatory filing acceptance this year for belantamab mafodotin combinations in the treatment of relapsed or refractory multiple myeloma based on the results of the DREAMM-7 and DREAMM-8 trials. In 2024, belantamab mafodotin combinations have been accepted for review in the European Union, Japan (with priority review), United Kingdom, Canada and Switzerland (with priority review for DREAMM-8). In China, the National Medical Products Administration has granted Breakthrough Therapy Designation for belantamab mafodotin in combination with bortezomib and dexamethasone, as well as priority review for the regulatory application based on the results of DREAMM-7.

Powered by WPeMatico

Over 200 contractual doctors in UP to get 1-year extension

Lucknow: Amid a shortage of doctors in the state, the Directorate General of Medical Health has announced a one-year extension for over 200 doctors working on a contractual basis under Chief Medical Officers (CMOs) across the state. 

The order issued by Dr Brijesh Rathore, the Director General of Medical Health, instructs Chief Medical Officers to assess whether the doctors are ready to maintain their positions and evaluate their performance before approving any extensions. Furthermore, the CMOs are required to report the current status of unfilled positions back to the directorate for further action.

Also read- 22 per cent shortfall of specialist doctors in AP: CAG Report

However, doctors who have already served for two years after being selected via a walk-in recruitment process in November 2023 including one year of extension will not be eligible for further renewal. Instead, they must reapply through the walk-in recruitment process whenever new hiring is organized, stated the order. 

“According to the government order issued in June 2017 regarding the contractual posting of doctors, the period of extension can be for a maximum of one year, provided the fitness of the doctors for work and the quality of their work is deemed satisfactory,” stated the order from the DG health office.

As per HT news report, contractual doctors’ wages vary depending on the location of their posting, with higher wages offered in remote areas to attract professionals. Cities are categorized into different grades, with Grade A cities like Lucknow, Prayagraj, Agra, and Ghaziabad offering Rs 50,000 per month to MBBS doctors. Grade D cities, being farther from the state capital, offer higher pay, with MBBS doctors earning Rs 65,000 monthly. Specialists receive significantly higher remuneration, ranging from Rs 80,000 in Grade A cities to Rs 1,20,000 in Grade D cities.

Currently, around 200 MBBS doctors and nine specialists are working on a contractual basis across the state. Given the state’s gap of approximately 7,000 doctors against the 19,000 sanctioned posts, retaining doctors in contractual positions remains critical.

Also read- Viral video: Safdarjung Resident doctor abused by IPS officer, Doctors demand apology

Powered by WPeMatico

MBBS seat scam: Parents tricked, taken to Vellore Medical College by man pretending to be Priest

Police have arrested a 67-year-old man for duping parents of aspirants of crores of rupees by promising MBBS seats in a reputed Tamil Nadu medical college. The man reportedly pretended to be a priest to cheat people. He has now been arrested for allegedly running a scam by falsely promising MBBS seats under the staff quota at Vellore Medical College. The apprehended, Jacob Thomas of Koodal in Pathanamthitta, was arrested at the Chennai International Airport while attempting to flee to Malaysia.

Onmanorama Reports that Thomas introduced himself as a gospel worker and convinced families from Kerala and other states that he had close connections with Christian Medical College (CMC), Vellore, and an Anglican bishop.

For more information, click on the link below:

Powered by WPeMatico

Popular diabetes and obesity drugs also protect kidneys, study shows

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes. The findings were published in The Lancet Diabetes & Endocrinology.

Powered by WPeMatico

Adding temozolomide to radiation therapy improves survival in adult patients with slow-growing brain tumor, trial finds

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas. The randomized phase 3 trial E3F05 by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) tested whether combined therapy using temozolomide alongside radiation therapy is more effective than radiation therapy alone in these patients.

Powered by WPeMatico

Studies examine cost-effectiveness of maternal RSV vaccination and nirsevimab in infants

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.

Powered by WPeMatico

A robust tool for complex time-to-event data analysis in the context of myeloproliferative neoplasms

A new thesis from Karolinska Institutet shows the effectiveness of flexible parametric survival models in modeling multiple time-scales, providing a robust tool for complex time-to-event data analysis. The models were tested in the context of myeloproliferative neoplasms, a group of chronic hematologic malignancies in which the bone marrow makes too many red blood cells, white blood cells, or platelets.

Powered by WPeMatico